Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06585579

The Effect of Mucogyne® Ovule on Wound Healing (ORIGYNE)

ORIGYNE (MUCO232) - the Effect of Mucogyne® Ovule on Wound Healing

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
144 (estimated)
Sponsor
Biocodex · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

This clinical investigation is a post-market clinical follow-up performed to confirm the performance and safety of the Mucogyne® ovule medical device in promoting the process of wound healing, when used in accordance with its approved labelling, in the context of local cervicovaginal surgery.

Conditions

Interventions

TypeNameDescription
DEVICEMucogyne OvuleIn Mucogyne group, patient will receive 2 boxes of Mucogyne® ovule. 24 hours after intervention, the patient will apply Mucogyne® ovule, 1 ovule per day for 10 days, to be repeated as needed (for practices' homogenisation, after the 10th day, it is recommended to apply one ovule every second day, until EOS visit)

Timeline

Start date
2024-10-01
Primary completion
2025-08-01
Completion
2025-11-01
First posted
2024-09-05
Last updated
2024-09-05

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06585579. Inclusion in this directory is not an endorsement.

The Effect of Mucogyne® Ovule on Wound Healing (ORIGYNE) (NCT06585579) · Clinical Trials Directory